Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2016 | Cancer cachexia and novel targeted therapies

David Currow • 6 Nov 2016
NCRI 2016

David Currow, PhD, MPH, FRACP, FAChPM, FAHMS, GAICD of Flinders University, Adelaide, Australia discusses cancer cachexia and novel targeted therapies for its treatment at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK. Prof. Currow explains that there have been no options for treatment so far. There are, however, Phase III studies of novel agents including a ghrelin agonist, that are demonstrating effects on cachexia as he discusses. This suggests that there are possibilities for treatment.

More from David Currow

1:09
Anamorelin for cachexia for patients with NSCLC
David Currow • 4 Dec 2016
1:34
Symptom control in advanced cancer - key issues and what we can do about it
David Currow • 6 Nov 2016
1:14
Current treatments for cachexia
David Currow • 4 Dec 2016
1:54
The impact of chronic breathlessness on cancer patients
David Currow • 23 Jun 2016
The content of VJOncology is intended for healthcare professionals